(2-carboxamido)(3-amino)thiophene compounds

1. A method of treatment of a hyperproliferative disorder selected from breast cancer, head cancer, neck cancer, gastrointestinal cancer, leukemia, ovarian cancer, bronchial cancer, lung cancer, pancreatic cancer, sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, or prostate carcinoma, comprising administering an effective amount of a compound of Formula III:

wherein:

R12 is aryl, C 3-6 cycloalkyl, or heterocyclyl, each of which optionally is substituted with 1-6 independent halogen; hydroxy; nitro; protected amino, amino; acyl; substituted acyl; acylC 1-6 alkylsulfinyl; acylC 1-6 alkylsulfonyl; acyloxy; C 1-6 alkylaminoC 1-6 alkyl carbamoyloxy; aryl; cyano; heterocyclyl; C 2-6 alkenyl optionally substituted with acyl, substituted acyl, aryl or acyl-substituted aryl; C 2-6 alkynyl optionally substituted with amino, acylamino or substituted acylamino; C 1-6 alkyl optionally substituted with halogen, amino, C 1-6 alkylamino, acylamino, substituted acylamino, hydroxy, acyloxy, acylC 1-6 alkanoyloxy, acyl, substituted acyl, acylC 1-6 alkoxyimino, aryl or acyl substituted aryl; C 1-6 alkylthio optionally substituted with acyl or substituted acyl; alkoxy optionally substituted with aryl, substituted aryl, hydroxy, acyloxy, amino, lower alkylamino, protected amino, heterocyclyl, acyl substituted pyridyl, substituted acyl substituted pyridyl, halogen, acylC 1-6 alkylamino, N-protected acylC 1-6 alkylamino, N-acylC 1-6 alkyl-N-lower alkylamino, acyl, substituted acyl, acylamino, substituted acylamino, C 1-6 alkylhydrazinocarbonyl amino, hydroxyimino, acylC 1-6 alkoxyimino, substituted acylC 1-6 alkoxyimino, acylC 1-6 alkoxy, guanidino or N-protected guanidino; or C 2-6 alkenyloxy optionally substituted with acyl or substituted acyl substituents;

R22 is hydrogen; C 1-6 alkyl optionally substituted with hydroxy, aryl, or acyl; or C 3-6 cycloalkyl;

R32 is hydrogen; halogen; hydroxy; acyloxy; substituted acyloxy; C 1-6 alkyl optionally substituted with hydroxy or C 1-6 alkoxy; C 1-6 alkoxy optionally substituted with aryl, amino, protected amino, acyl, hydroxy, cyano or C 1-6 alkylthio; nitro; amino; acyl; substituted acyl; or C 3-6 cycloalkyloxy;

A 1 is NH;

E 1 is C 1-6 alkylene, C 2-6 alkenylene,

or E 1 is a group of the formula-G1-J1-in which

G1 is C 1-6 alkylene or

J1 is O or

wherein R 62 is hydrogen or N-protective group;

X 1 is S; and

Y 1 is aryl optionally substituted with 1-6 independent acyl, protected aminoC 1-6 alkanoyl, protected amino and nitro, amino and nitro or diamino substituents; or Y 1 is a condensed heterocyclyl optionally substituted with 1-6 halogen, acyl, C 1-6 alkoxy, hydroxy, guanidino, mercapto, acylamino, amino, heterocyclyl, cyanoamino, aminoC 1-6 alkyl(C 1-6 alkyl)amino, C 1-6 alkylamino, C 1-6 alkylamino(C 1-6 alkylamino), substituted heterocyclyl, C 1-6 alkylhydrazino, aryloxy, C 1-6 alkylthio, aryl, protected amino, N-protected C 1-6 alkylamino(C 1-6 alkyl)amino, N-protected aminoC 1-6 alkyl(N′-C 1-6 alkyl)amino, aminoC 1-6 alkyl(N-C 1-6 alkyl)amino, C 1-6 alkylamino(C 1-6 alkyl) (N-C 1-6 alkyl)amino, or C 1-6 alkoxy(C 1-6 alkyl)amino substituents, or a C 1-6 alkyl substituent further optionally substituted with aryl, arC 1-6 alkoxy, cyano, hydroxyimino, mercapto, C 1-6 alkylamino, acyloxy, halogen, C 1-6 alkoxy, protected hydroxy, hydroxy, C 1-6 alkoxyaryl, protected amino, amino, heterocyclyl, or substituted heterocyclyl sub-substituents;

provided that Y 1 is phenyl optionally substituted with C 1-6 alkyl or acyl; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , further comprising the step of administering an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.

3. The method of claim 1 wherein the hyperproliferative disorder is breast cancer, head cancer, or neck cancer.

4. The method of claim 1 wherein the hyperproliferative disorder is gastrointestinal cancer.

5. The method of claim 1 wherein the hyperproliferative disorder is leukemia.

6. The method of claim 1 wherein the hyperproliferative disorder is ovarian, bronchial, lung, or pancreatic cancer.

7. The method of claim 1 wherein the hyperproliferative disorder is lung cancer.

8. The method of claim 1 wherein the hyperproliferative disorder is head and neck cancer.

9. The method of claim 1 wherein the hyperproliferative disorder is sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, or prostate carcinoma.